<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02991144</url>
  </required_header>
  <id_info>
    <org_study_id>301OTC01</org_study_id>
    <secondary_id>2016-001057-40</secondary_id>
    <nct_id>NCT02991144</nct_id>
  </id_info>
  <brief_title>Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset OTC Deficiency</brief_title>
  <acronym>CAPtivate</acronym>
  <official_title>A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1/2, open-label dose-finding safety study of single ascending doses of DTX301 in&#xD;
      adults with late-onset OTC Deficiency&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1/2, open-label, single arm, multicenter, safety and dose finding study of&#xD;
      DTX301 in adults with late-onset OTC deficiency. The primary objective of the study is to&#xD;
      determine the safety of single IV doses of DTX301.&#xD;
&#xD;
      Eligible subjects will receive a single IV infusion of DTX301. Dose escalation will be&#xD;
      conducted according to a model that uses the collected data to predict the safety profile of&#xD;
      the dose in order to determine the optimal biological dose (OBD). The decision to proceed to&#xD;
      the next dose cohort will be made after the data monitoring committee (DMC) has evaluated the&#xD;
      safety data for all subjects in a dosing cohort.&#xD;
&#xD;
      Subjects will be followed for 52 weeks after dosing. After completion of this study, subjects&#xD;
      will be asked to enroll in a 4-year extension study to evaluate the long term (a total of 5&#xD;
      years) safety and efficacy of DTX301.&#xD;
&#xD;
      This study was previously posted by Dimension Therapeutics, which has been acquired by&#xD;
      Ultragenyx.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of treatment-related adverse events by dosing group</measure>
    <time_frame>52 weeks</time_frame>
    <description>The incidence of adverse events (AEs), treatment-emergent adverse events (TEAEs), and serious adverse events (SAEs) for each dosing cohort, assessed by severity and relationship to study product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in baseline in ureagenesis rate</measure>
    <time_frame>52 weeks</time_frame>
    <description>The change from baseline in the rate of ureagenesis (as measured by the generation of [13C]urea) as determined over time to 52 weeks after the IV administration of DTX301. Sodium acetate is used as a tracer to measure the rate of ureagenesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in baseline 24 hour area under the curve of ammonia</measure>
    <time_frame>52 weeks</time_frame>
    <description>The change from baseline (Day 0) in area under the curve from time zero to 24 hours (AUC0 24) for serum ammonia over time to 52 weeks after IV administration of DTX301</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Ornithine Transcarbamylase (OTC) Deficiency</condition>
  <arm_group>
    <arm_group_label>Dose 1: 2.0 × 10^12 GC/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2: 6.0 × 10^12 GC/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3: 1.0 × 10^13 GC/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DTX301 (scAAV8OTC) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing Process Optimization at Optical Biological Dose (OBD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral prednisone (or prednisolone), 60 mg tapered over 9 weeks, initiated before dosing with DTX301. DTX301 (scAAV8OTC; optimal biologic dose) will be administered as a single peripheral IV infusion. Sodium acetate is used as a tracer to measure the rate of ureagenesis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>scAAV8OTC</intervention_name>
    <description>non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)</description>
    <arm_group_label>Dose 1: 2.0 × 10^12 GC/kg</arm_group_label>
    <arm_group_label>Dose 2: 6.0 × 10^12 GC/kg</arm_group_label>
    <arm_group_label>Dose 3: 1.0 × 10^13 GC/kg</arm_group_label>
    <arm_group_label>Dosing Process Optimization at Optical Biological Dose (OBD)</arm_group_label>
    <other_name>DTX301</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral prednisone</intervention_name>
    <description>Initiated before dosing with DTX301, sustained for 4 weeks, followed by tapering</description>
    <arm_group_label>Dosing Process Optimization at Optical Biological Dose (OBD)</arm_group_label>
    <other_name>Oral prednisolone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Males and females ≥18 years of age with documented diagnosis of late onset (defined as&#xD;
             first manifestation of signs and symptoms at ≥1 month of age) OTC deficiency,&#xD;
             confirmed via enzymatic, biochemical, or molecular testing&#xD;
&#xD;
          2. Documented history of ≥1 symptomatic hyperammonemia event with ammonia ≥100 µmol/L.&#xD;
&#xD;
          3. Subject's OTC deficiency is stable as evidenced by either a) no clinical symptoms of&#xD;
             hyperammonemia OR b) an ammonia level &lt;100 µmol/L within the 4 week period preceding&#xD;
             the Screening visit.&#xD;
&#xD;
          4. On ongoing daily stable dose of ammonia scavenger therapy for ≥4 weeks.&#xD;
&#xD;
          5. Males and all females of childbearing potential must be willing to use effective&#xD;
             contraception at the time of administration of gene transfer and for the 52 weeks&#xD;
             following administration of DTX301&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. At Screening or Baseline (Day 0), plasma ammonia level ≥ 100 μmol/L for patients who&#xD;
             historically maintain normal ammonia levels; OR plasma ammonia level ≥ 200 μmol/L for&#xD;
             patients who historically are not able to fully control ammonia levels with baseline&#xD;
             management; OR signs and symptoms of hyperammonemia.&#xD;
&#xD;
          2. Liver transplant, including hepatocyte cell therapy/transplant.&#xD;
&#xD;
          3. History of liver disease&#xD;
&#xD;
          4. Significant hepatic inflammation or cirrhosis&#xD;
&#xD;
          5. Serum creatinine &gt;2.0 mg/dL.&#xD;
&#xD;
          6. Participation in another investigational medicine study (including another gene&#xD;
             transfer trial) within 3 months of Screening&#xD;
&#xD;
          7. Pregnant or nursing&#xD;
&#xD;
        Note additional inclusion/exclusion criteria may apply, per protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ultragenyx Pharmaceutical Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029-6508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Cleveland Medical Center/Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta's Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruzes</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology &amp; Neurosurgery</name>
      <address>
        <city>London</city>
        <state>London City</state>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 9, 2016</study_first_submitted>
  <study_first_submitted_qc>December 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gene Transfer</keyword>
  <keyword>OTC Deficiency</keyword>
  <keyword>Urea Cycle Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

